Are different hemodynamic patterns of antihypertensive drugs clinically important?
- PMID: 2200691
- DOI: 10.1007/BF01409481
Are different hemodynamic patterns of antihypertensive drugs clinically important?
Abstract
Since vascular resistance is elevated in hypertension, it is suggested that vasodilators lower the blood pressure by a physiologic mechanism and therefore must be more useful than cardiac output-lowering drugs. This is not entirely correct. Drugs that lower cardiac output are also relative vasodilators, but the vasodilation occurs at a lower level of cardiac output. It is also not necessarily true that all vasodilators are good antihypertensive agents. The clinical profile of a vasodilator depends on its effect on the venous return, cardiac output, regional blood flow, renin-angiotensin system, and sympathetic reflexes. From the viewpoint of hemodynamics, an ideal antihypertensive drug is a vasodilator that does not excessively increase cardiac output, causes no fluid retention, does not induce a great deal of venodilation, and does not elicit substantial neurohumoral counterregulation. Angiotensin-converting-enzyme inhibitors, some calcium antagonists, and some combined alpha/beta-blocking agents come close to satisfying the hemodynamic definition of an ideal antihypertensive drug.
Similar articles
-
[Pharmacological basis of antihypertensive drug therapy].Praxis (Bern 1994). 2004 May 12;93(20):847-56. doi: 10.1024/0369-8394.93.20.847. Praxis (Bern 1994). 2004. PMID: 15195836 German.
-
Renal haemodynamics in hypertension: effects of antihypertensive drugs.J Hum Hypertens. 1993 Feb;7 Suppl 1:S42-5. J Hum Hypertens. 1993. PMID: 8487249 Review.
-
Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy.Am J Med. 1987 Jan 5;82(1A):36-43. doi: 10.1016/0002-9343(87)90142-2. Am J Med. 1987. PMID: 2879462
-
Hemodynamic effects of antihypertensive drugs.Am Fam Physician. 1983 Jun;27(6):137-42. Am Fam Physician. 1983. PMID: 6134461
-
Hemodynamic and counterregulatory effects of calcium antagonists in hypertension.J Cardiovasc Pharmacol. 1988;12 Suppl 6:S39-43. doi: 10.1097/00005344-198812006-00010. J Cardiovasc Pharmacol. 1988. PMID: 2468904 Review.
Cited by
-
Obesity as a determinant for response to antihypertensive treatment.BMJ. 1993 Aug 28;307(6903):537-40. doi: 10.1136/bmj.307.6903.537. BMJ. 1993. PMID: 8400973 Free PMC article. Clinical Trial.
-
Antihypertensive profile of carvedilol.Clin Investig. 1992;70 Suppl 1:S43-52. doi: 10.1007/BF00207611. Clin Investig. 1992. PMID: 1350484 Review.
-
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.J Clin Hypertens (Greenwich). 2004 Mar;6(3):116-25. doi: 10.1111/j.1524-6175.2004.03216.x. J Clin Hypertens (Greenwich). 2004. PMID: 15010644 Free PMC article. Clinical Trial.
-
Stress response and antihypertensive treatment.Drugs. 1993;46 Suppl 2:133-40; discussion 141. doi: 10.2165/00003495-199300462-00022. Drugs. 1993. PMID: 7512466 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical